Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HRTX 
Heron Therapeuti (HRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: HRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.75
1 Year Target Price $4.75
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.87% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 213.08M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 3 | Beta 1.16 | 52 Weeks Range 1.04 - 2.68 | Updated Date 08/29/2025 |
52 Weeks Range 1.04 - 2.68 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.01 | Actual -0.02 |
Profitability
Profit Margin -0.62% | Operating Margin (TTM) -4.4% |
Management Effectiveness
Return on Assets (TTM) 0.34% | Return on Equity (TTM) -2408.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 344586845 | Price to Sales(TTM) 1.42 |
Enterprise Value 344586845 | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 45.73 | Shares Outstanding 153292000 | Shares Floating 106156103 |
Shares Outstanding 153292000 | Shares Floating 106156103 | ||
Percent Insiders 0.74 | Percent Institutions 87.88 |
Upturn AI SWOT
Heron Therapeuti
Company Overview
History and Background
Heron Therapeutics, Inc. (HRTX) was founded in 1998. It's a commercial-stage biotechnology company focused on developing and commercializing novel solutions to address unmet medical needs, primarily in pain management and oncology.
Core Business Areas
- Acute Care: Developing and commercializing non-opioid solutions for acute pain management in the hospital and ambulatory surgery center settings. Heron's primary focus here is its Zynrelef product.
- Oncology Care: Developing therapies to reduce chemotherapy-induced nausea and vomiting (CINV) and other supportive care needs for cancer patients. Heron offers products such as Sustol and Cinvanti in this segment.
Leadership and Structure
Barry Quart, Pharm.D., is the Chief Executive Officer. The company has a typical biotech organizational structure with departments for research and development, clinical operations, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Zynrelef: Zynrelef is a long-acting, local anesthetic approved for postoperative pain management. Zynrelef's market share is growing in the postsurgical pain market, competing with local anesthetics such as bupivacaine and generics. Competitors include Pacira BioSciences (EXPA) with Exparel.
- Sustol: Sustol is a subcutaneous injection used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). The competitors in this market are aprepitant (Emend), palonosetron (Aloxi), and generics. Sustol has a small but stable market share.
- Cinvanti: Cinvanti is an intravenous emulsion formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). Competitors include Emend IV (Merck).
Market Dynamics
Industry Overview
The pharmaceutical industry, especially in pain management and oncology supportive care, is highly competitive and regulated. Demand for non-opioid pain solutions is increasing due to the opioid crisis.
Positioning
Heron is positioned as an innovator in non-opioid pain management and CINV prevention. Its competitive advantage lies in its proprietary Biochronomer drug delivery technology for extended-release formulations.
Total Addressable Market (TAM)
The TAM for post-operative pain management and CINV is estimated to be in the billions of dollars. Heron is positioned to capture a significant share through its differentiated products, particularly Zynrelef.
Upturn SWOT Analysis
Strengths
- Proprietary Biochronomer drug delivery technology
- Approved non-opioid pain management product (Zynrelef)
- Established oncology supportive care portfolio (Sustol, Cinvanti)
- Experienced management team
Weaknesses
- Relatively small company size compared to competitors
- High operating expenses
- Dependence on key products for revenue
- Potential for generic competition
Opportunities
- Expanding Zynrelef market share in post-surgical pain
- Developing new formulations using Biochronomer technology
- Partnerships and collaborations for commercialization
- Acquiring complementary products or technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory changes affecting drug approvals and reimbursement
- Patent challenges and litigation
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- Eisai (ESALY)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Heron's advantage lies in its non-opioid pain solution, Zynrelef, but it competes with larger, more established companies like Pacira in the postsurgical pain market. In CINV, Merck and Eisai have established products and distribution networks.
Major Acquisitions
No recent significant acquisitions
- Year: 2000
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Heron has experienced revenue growth driven by Zynrelef adoption, but profitability remains a challenge.
Future Projections: Analyst estimates suggest continued revenue growth driven by Zynrelef, with potential for profitability in the next few years. (Note: These are projections and may not accurately predict future results.)
Recent Initiatives: Focusing on expanding Zynrelef sales and marketing efforts. Streamlining operations to reduce expenses. Exploring potential partnerships for new product development.
Summary
Heron Therapeutics is a biotech company focused on non-opioid pain management and oncology supportive care. Zynrelef represents a significant growth opportunity, but profitability remains a challenge. The company faces competition from larger pharmaceutical companies and regulatory risks. However, they have seen an increase in revenue and a decrease in negative net income. They must continue revenue growth and manage costs to achieve sustained profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry News and Publications
- Heron Therapeuti Investor Relations
- YCHARTS
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice, and investors should conduct their own due diligence before making any investment decisions. Market conditions and company performance can change, impacting future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heron Therapeuti
Exchange NASDAQ | Headquaters Cary, NC, United States | ||
IPO Launch date 1987-08-26 | CEO & Director Mr. Craig Alexander Collard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.herontx.com |
Full time employees 122 | Website https://www.herontx.com | ||
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.